Correction of Psoriatic T Cell Signatures by Deucravacitinib
ConditionPsoriasis Vulgaris
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of California, San Francisco
About this trial
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Eligibility criteria
Qualifiers
18 years of age or older
Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician's Global Assessment (sPGA) 3 and above)
Disqualifiers
taking systemic immunosuppressives in the last 12 weeks
pregnancy
severe immunodeficiency (either from genetic or infectious causes).
tuberculosis or other active serious infection
Trial design
Treatments tested in this trial
- deucravacitinib
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, San Francisco
Lead sponsor
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov